{"id":"sitagliptin-and-acarbose","safety":{"commonSideEffects":[{"rate":"15–30","effect":"Gastrointestinal disturbances (diarrhea, flatulence, abdominal discomfort)"},{"rate":"5–10","effect":"Hypoglycemia"},{"rate":"5–10","effect":"Headache"},{"rate":"5–10","effect":"Nasopharyngitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sitagliptin is a DPP-4 inhibitor that prolongs the action of incretin hormones (GLP-1 and GIP), which stimulate insulin secretion in response to meals. Acarbose is an alpha-glucosidase inhibitor that delays carbohydrate breakdown and absorption in the small intestine, reducing postprandial glucose spikes. Together, they provide complementary mechanisms to lower blood glucose in type 2 diabetes.","oneSentence":"This combination reduces blood glucose by inhibiting dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and slowing carbohydrate digestion via alpha-glucosidase inhibition.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:08:20.867Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT05035849","phase":"NA","title":"Comparison of the FGM Profiles in Patients of Type 2 Diabetes Treated With Sitagliptin and Acarbose","status":"COMPLETED","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2020-01-30","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT01490918","phase":"PHASE4","title":"Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients","status":"COMPLETED","sponsor":"The Catholic University of Korea","startDate":"2012-04","conditions":"Type 2 Diabetes Mellitus","enrollment":165},{"nctId":"NCT02072096","phase":"PHASE4","title":"A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-02","conditions":"Diabetes Mellitus, Type 2","enrollment":192},{"nctId":"NCT01709305","phase":"PHASE4","title":"A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-08","conditions":"Type 2 Diabetes Mellitus","enrollment":5570},{"nctId":"NCT01177384","phase":"PHASE3","title":"Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-25","conditions":"Type 2 Diabetes Mellitus","enrollment":380},{"nctId":"NCT02527993","phase":"PHASE4","title":"Treatment of Hypoglycemia Following Gastric Bypass Surgery","status":"COMPLETED","sponsor":"Zealand University Hospital","startDate":"2015-10","conditions":"Hypoglycemia, Obesity, Surgery","enrollment":11},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":886172},{"nctId":"NCT01863147","phase":"PHASE4","title":"Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease","status":"COMPLETED","sponsor":"Wuhan General Hospital of Guangzhou Military Command","startDate":"2013-07","conditions":"Newly Diagnosed Type 2 Diabetes, Coronary Artery Disease","enrollment":66},{"nctId":"NCT01624116","phase":"NA","title":"Comparison of Hypoglycaemic Regimens During Ramadan Fasting in Type 2 Diabetes","status":"COMPLETED","sponsor":"Services Hospital, Lahore","startDate":"2011-08","conditions":"Diabetes, Type 2","enrollment":161},{"nctId":"NCT00950534","phase":"PHASE4","title":"Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary Care","status":"TERMINATED","sponsor":"Sanofi","startDate":"2009-07","conditions":"Diabetes Mellitus, Type 2","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":59,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"sitagliptin and acarbose","genericName":"sitagliptin and acarbose","companyName":"Nanjing First Hospital, Nanjing Medical University","companyId":"nanjing-first-hospital-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces blood glucose by inhibiting dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and slowing carbohydrate digestion via alpha-glucosidase inhibition. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}